The genetics of cystic fibrosis lung disease

Thorax

Volumn 53, Issue 5, 1998, Pages 389-397

  Davidson, Donald J ^a   Porteous, David J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR PROTEIN, HUMAN;

BACTERIAL PNEUMONIA; CYSTIC FIBROSIS; GENE MUTATION; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC POLYMORPHISM; HUMAN; INFECTION SENSITIVITY; LUNG FIBROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; BACTERIAL INFECTION; DISEASE MODEL; GENE DELETION; GENETICS; MICROBIOLOGY; MOUSE; MUTATION; RECESSIVE GENE;

ANIMALS; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; GENE DELETION; GENES, RECESSIVE; HUMANS; MICE; MUTATION;

EID: 0031810850     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.5.389     Document Type: Review

References (54)

1. Davis PB, Drumm M, Konstan MW. Cystic-fibrosis. Am J Respir Crit Care Med 1996;154:1229-56.
2. Anderson MP, Sheppard DN, Berger HA, et al. Chloride channels in the apical membrane of normal and cystic fibrosis airway and intestinal epithelia. Am J Physiol 1992;263:L1-L14.
3. Welsh MJ. Cystic fibrosis. In: Schultz SG, ed. Molecular biology of membrane transport disorders. New York: Plenum Press, 1996: 605-23.
4. Dorin JR, Alton EWFW, Porteous DJ. Mouse models for cystic fibrosis. In: Dodge JA, Brock DJH, Widdicombe JH, eds. Cystic fibrosis current topics. Chichester: John Wiley, 1994: 3-31.
5. McLachlan G, Porteous DJ. The role of mouse models in the development of new therapies for cystic fibrosis. In: Houdebine LM, ed. Transgenic animals: generation and use. Amsterdam: Harwood Academic Press, 1997: 435-44.
6. Tsui LC, Markiewicz D, Zielinski J, et al. Mutation analysis in cystic fibrosis. In: Dodge JA, Brock DJH, Widdicombe JH, eds. Cystic fibrosis current topics. Chichester: John Wiley, 1992: 27-44.
7. Estivill X. Complexity in a monogenic disease. Nature Genetics 1996;12:348-50.
8. Chu CS, Trapnell BC, Curristin SM, Cutting GR, Crystal RG. Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold-1 in respiratory epithelial messenger-RNA transcripts of the cystic-fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic-fibrosis. Journal of Clinical Investigation 1992;90:785-90.
9. Mak V, Jarvi KA, Zielenski J, et al. Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens. Hum Mol Genet 1997;6:2099-107.
10. Johnson LG, Olsen JC, Sarkadi B, et al. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nature Genetics 1992;2:21-5.
11. Dorin JR, Farley R, Webb S, et al. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Therapy 1996;3:797-801.
12. Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nature Genetics 1996;13:280-7.
13. Dorin JR, Davidson DJ, Innes BA, et al. Respiratory tract phenotype in different inbred and congenic CF mice strains. Pediatr Pulmonol 1997;S14:182.
14. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995;269: 847-50.
15. Devidas S, Guggino WB. The cystic fibrosis transmembrane conductance regulator and ATP. Curr Opin Cell Biol 1997; 9:547-52.
16. Barasch J, Kiss B, Prince A, et al. Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991;352: 70-3.
17. Govan JW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-74.
18. Grimwood K, Armstrong D, Carlin J, et al. Acquisition of Pseudomonas aeruginosa in young infants. Pediatr Pulmonol 1997;S14:133
19. Hancock RW. Peptide antibiotics. Lancet 1997;349:418-22.
20. Claireaux AK. Fibrocystic disease of the pancreas in the newborn. Arch Dis Child 1956;31:22-7.
21. Oppenheimer EH, Esterly JR. Pathology of cystic fibrosis: review of the literature and comparison with 146 autopsied cases. In: Rosenberg HS, Bolande RP, eds. Perspectives in pediatric pathology. Volume 2. New York: Yearbook Medical Publishers, 1975: 241-78.
22. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82.
23. Drittanti L, Masciovecchio MV, Gabbarini J, et al. Cystic fibrosis: gene therapy or preventive gene transfer? Gene Therapy 1997;4:1001-3.
24. Davidson DJ, Dorin JR, McLachlan G, et al. Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens. Nature Genetics 1995;9:351-7.
25. Zahm JM, Gaillard D, Dupuit F, et al. Early alterations in airway mucociliary clearance and inflammation of the lamina propria in CF mice. Am J Physiol: Cell Physiol 1997; 41:C853-9.
26. van Heeckeren A, Walenga R, Konstan MW, et al. Excessive inflammatory response of cystic fibrosis mice to broncho-pulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997;100:2810-5.
27. Harris A. Towards an ovine model of cystic fibrosis. Hum Mol Genet 1997;6:2191-3.
28. Puchelle E, Jacquot J, Beck G, et al. Rheological and transport properties of airway secretions in cystic fibrosis relationships with the degree of infection and severity of the disease. Eur J Cin Invest 1985;15:389-94.
29. Yeates DB, Sturgess JM, Kahn SR, et al. Mucociliary transport in trachea of patients with cystic fibrosis. Arch Dis Child 1976;51:28-33.
30. Regnis JA, Robinson M, Bailey DL, et al. Mucociliary clearance in patients with cystic-fibrosis and in normal subjects. Am J Respir Crit Care Med 1994;150:66-71.
31. Afzelius BA. Ciliary dysfunction. In: Crystal RG, West JB, Weibel ER, Barnes PJ, eds. The Lung; Scientific Foundations. 2nd ed. New York: Lippincott-Raven, 1997: 2573-8.
32. Kerem E, Bistrizer T, Hanukoglu A, et al. Respiratory disease in patients with the systemic form of pseudo-hypoaldosteronism type 1. Pediatr Pulmonol 1997;S14:78.
33. Li JD, Dohrman AF, Gallup M, et al. Transcriptional activation of mucin by Pseudomonas aeruginosa lipopolysaccharide in the pathogenesis of cystic fibrosis lung disease. Proc Natl Acad Sci USA 1997;94:967-72.
34. Smith JJ, Travis SM, Greenberg EP, et al. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-36.
35. Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997;88:553-60.
36. Harder J, Bartels J, Christophers E, et al. A peptide antibiotic from human skin. Nature 1997;387:861.
37. Singh P, Welsh MJ. Components of airway surface fluid have synergistic antimicrobial activity. Pediatr Pulmonol 1997; S14:323.
38. Widdicombe JH, Fischer H, Lee Y-C, et al. Elemental composition of airway surface fluid. Pediatr Pulmonol 1997;S14: 74.
39. Quinton PM. Cystic fibrosis: old questions, new answers. The second Joseph Levy Memorial Lecture 1996:1-44.
40. Knowles MR, Robinson JM, Wood RE, et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest 1997;100:2588-95.
41. Huttner KM, Kozak CA, Bevins CL. The mouse genome encodes a single homolog of the antimicrobial peptide human beta-defensin-1. FEBS Lett 1997;413:45-9.
42. Morrison GM, Davidson DJ, Kilanowski FM, et al. Mouse beta defensin-1 is a functional homologue of human beta defensin-1. Mamm Genome (in press).
43. Saiman L, Prince A. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest 1993;92:1875-80.
44. Debentzmann S, Roger P, Dupuit F, et al. AsialoGM1 is a receptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells. Infect Immun 1996;64: 1582-8.
45. Davies JC, Stern M, Dewar A, et al. CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. Am J Respir Cell Mol Biol 1997;16:657-63.
46. Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hyper susceptibility of cystic fibrosis patients to lung infections. Science 1996;271:64-7.
47. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997;94:12088-93.
48. Carroll TP, Morales MM, Fulmer SB, et al. Alternate translation initiation codons can create functional forms of cystic fibrosis transmembrane conductance regulator. J Biol Chem 1995;270:11941-6.
49. Porteous DJ, Davidson DJ. Cystic fibrosis lung infection cleared up? Nature Medicine 1997;2:1317-8.
50. Borthwick DW, West JD, Keighren MA, et al. Murine submucosal glands are clonally derived and show a Cftr dependent distribution pattern. Submitted 1998.
51. Sanders A, Crystal RG. Consequences to the lung of specific deficiencies in host defence. In: Crystal RG, West JB, Weibel ER, Barnes PJ, eds. The Lung: Scientific Foundations. 2nd ed. New York: Lippincott-Raven, 1997: 2367-70.
52. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992;256:774-9.
53. Delaney SJ, Wainwright BJ. New pharmaceutical approaches to the treatment of cystic fibrosis. Nature Medicine 1996;2:392-3.
54. Ho L-P, McLachlan G. Gene therapy clinical trials for cystic fibrosis (viral and non-viral approaches). In: Rolland A, ed. Advanced gene delivery: from concepts to pharmaceutical products. New York: Harwood Academic Publishers, 1997: in press.